A global antiB cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome.

Claire DossierBenjamin PrimChristelle MoreauThérésa KwonAnne MaisinSylvie NathansonChristiane De GennesKatia BarsottiAbdelmajid BourrassiJulien HoganGeorges Deschenes

Published in: Pediatric nephrology (Berlin, Germany) (2020)

Global antiB cell strategy combining obinutuzumab and daratumumab induces prolonged peripheral B cell depletion and remission in children with difficult-to-treat SDNS.

Keyphrases

single cell
multiple myeloma
cell therapy
young adults
rheumatoid arthritis
chronic lymphocytic leukemia
disease activity